Antonio Herold
Psychiatric/Mental Health · Havre de Grace, MDNPI 1588286520
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,875 of the $22,569 with a category attached, or 65.9%. AbbVie accounts for 75.4% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $17,753, more than ten times the $299 reported in 2021. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $76.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$17K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$727
- Supernus Pharmaceuticals, Inc.$532
- Johnson & Johnson$457
- Teva Pharmaceuticals USA, Inc.$404
- plus $2K from 10 others
What the payments were for
- Speaking & faculty fees$14,87566%
- Travel & lodging$5042%
- Food & beverage$7,07231%
- Education$1181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 107 | $17,027 |
| Otsuka America Pharmaceutical, Inc. | 30 | $1,106 |
| Alkermes, Inc. | 28 | $727 |
| Supernus Pharmaceuticals, Inc. | 15 | $532 |
| Johnson & Johnson | 14 | $457 |
| Teva Pharmaceuticals USA, Inc. | 10 | $404 |
| Axsome Therapeutics, Inc. | 13 | $395 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $372 |
| Vanda Pharmaceuticals Inc. | 11 | $326 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $255 |
| Lundbeck LLC | 12 | $238 |
| Corium, LLC | 4 | $190 |
| Neurocrine Biosciences, Inc. | 7 | $184 |
| Sage Therapeutics, LLC | 6 | $136 |
| E.r. Squibb & Sons, L.L.C. | 5 | $132 |
| USWM, LLC | 5 | $88 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$12,723
- ARISTADA$429
- ABILIFY MAINTENA$354
- QELBREE$230
- REXULTI$200
- SPRAVATO$127
- Azstarys$125
- ABILIFY ASIMTUFII$122
- Auvelity$121
- Austedo XR$110
- ARISTADA INITIO$107
- VIVITROL$100
How this compares
$22,569 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 23 | $52,859 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $1,333 |
| Bupropion XlBupropion Hcl | 42 | $1,206 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 29 | $859 |
| Buspirone Hcl | 56 | $507 |
| Mirtazapine | 29 | $411 |
| Quetiapine Fumarate | 17 | $392 |
| Escitalopram Oxalate | 32 | $326 |
| Carbamazepine ErCarbamazepine | 12 | $286 |
| Sertraline Hcl | 71 | $281 |
| Aripiprazole | 21 | $255 |
| Trazodone Hcl | 32 | $197 |
| Benztropine Mesylate | 17 | $111 |
| Gabapentin | 11 | $106 |
| Fluoxetine Hcl | 27 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $17,027 | $52,85923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Other psychiatric/mental health in Havre de Grace
- Joyce AwujorHavre de Grace$5K
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Michelle WilliamsColumbia$158K
- Kristin ClemensGaithersburg$36K
- Paul KlaverweidenFruitland$17K
- Margaret WebbAberdeen$16K
- Susan KrausTowson$16K
- Anyinke AtabongRockville$15K
- Zenatsehay GebretsadikColumbia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.